Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31631787 | 0.94 | ALDH1A1 (0.57) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL692277 | 0.94 | ALDH1A1 (0.57) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL1187473 | 0.86 | ALDH1A1 (0.65) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL10394357 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL4813783 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL29950688 | 0.84 | ALDH1A1 (0.68) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL28938618 | 0.81 | ALDH1A1 (0.59) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL5498049 | 0.81 | ERN1 (0.41) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL7401545 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC | |
| SCHEMBL20488498 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4ETSHRTDP1PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | US | disclosed |
| WO-2025032440-A1 | KLF2 INDUCING COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4476229-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | Riparian Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-118974057-A | KLF2 inducers and methods of use thereof | 里帕里安制药股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2023150374-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150374-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | RIPARIAN PHARMACEUTICALS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| CN-102127023-A | 7-membered ring compound, process for producing the same, and use thereof | DAIICHI ASUBIO PHARMA CO LTD | 2011-07-20 | — | — | CN | disclosed |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| US-7888348-B2 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-15 | — | — | US | disclosed |
| CN-101160290-B | 7-membered ring compound, process for producing the same, and pharmaceutical use thereof | DAIICHI SANKYO CO LTD | 2011-01-19 | — | — | CN | disclosed |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | ASUBIO PHARMA CO., LTD (JP) | 2009-10-08 | — | — | US | disclosed |
| CN-101495463-A | Seven-membered ring compound, production method thereof and pharmaceutical use thereof | ASUBIO PHARMA CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2025672-A1 | SEVEN-MEMBERED RING COMPOUND, PRODUCTION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| CN-101160290-A | 7-membered ring compound, process for producing the same, and pharmaceutical use thereof | ASUBIO PHARMA CO LTD (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1820798-A1 | 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Asubio Pharma Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ALDH1A1 761/4885KDM4E 2755/4885TSHR 325/4885 |
| US-20250171460-A1 | INDUCERS OF KLF2 AND METHODS OF USE THEREOF | SREBF2, LIPG, KLF5 | ALDH1A1 1828/4885KDM4E 999/4885TSHR 4210/4885 |
| US-20090111796-A1 | 7-membered ring compound and method of production and pharmaceutical application thereof | CMA1, CPA3, SI | ALDH1A1 1889/4885KDM4E 3685/4885TSHR 3978/4885 |
| US-20250109143-A1 | KLF2 INDUCING DEUTERATED COMPOUNDS AND USES THEREOF | KLF5, KLF10, SREBF2 | ALDH1A1 2822/4885KDM4E 382/4885TSHR 4207/4885 |
| US-20090253683-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | ALDH1A1 1889/4885KDM4E 3685/4885TSHR 3978/4885 |
| US-20110166342-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | ALDH1A1 1889/4885KDM4E 3685/4885TSHR 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.